How Do Emerging Options Address the Signs and Symptoms of Dry Eye Disease?

0.50 CME
0.50 CME WITH ABO CONTINUING CERTIFICATION
30 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

How Do Emerging Options Address the Signs and Symptoms of Dry Eye Disease?

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Oyster Point Pharma, Inc.


Activity Description

Dry eye disease (DED) is highly prevalent, but frequently under-diagnosed and under-treated. An estimated 5% to 15% of Americans have DED, but the actual figure may be higher, as DED is often underdiagnosed. Dry eye disease has a significant impact on work and other activities, and recent years have seen a growing understanding of the deleterious effects that DED and other ocular surface diseases can have on ocular surgery. With increasing understanding of the extent and impact of DED, there is a growing number of emerging treatment options. Clinicians must recognize the patients who are at risk for developing significant disease, and which of the available therapies are best suited to their needs. In this activity, expert faculty discuss the burden and risk factors of DED and the currently available therapies. They also will explore the mechanisms of action and available clinical data supporting the use of novel emerging therapies under investigation for treatment of DED.


Target Audience

The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with dry eye disease.


Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the efficacy and safety of new and emerging treatment options for dry eye disease.


Activity Chair

Stephen C. Pflugfelder, MD
Professor of Ophthalmology
Director of Ocular Surface Center
Baylor College of Medicine
Houston, TX


Faculty

Francis S. Mah, MD
Director, Cornea Service
Co-Director, Refractive Surgery
Scripps Clinic
La Jolla, CA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, September 13, 2021, to September 12, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Francis S. Mah, MD
Consulting Fee: Aerie, Alcon, Allergan, Aperta, Avellino, Azura, Bausch + Lomb, BlephEx, Dompè, Eyenovia, EyePoint, Eyevance, Glaukos, Ivantis, iView, J&J Vision, Kala, Mallinckrodt, Nevakar, Novartis, NuSight, Ocular Therapeutix, Okogen, Omeros, Oyster Point, PolyActiva, Sight Sciences, Sun, Thea
Ownership Interest: Avellino, iView, Ocular Science, Okogen, Sydnexis

Stephen C. Pflugfelder, MD
Consulting Fee: Dompé, Kala, Novartis, Oyster Point
Contracted Research: Dompé, Regeneron

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com